The Board of Directors of Celltrion, Inc. has authorized a buyback plan on December 27, 2024.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
179,600.00 KRW | -0.77% |
|
-0.06% | -4.21% |
02-04 | South Korean Shares Rally on US Tariff Delay; Celltrion Shares Rise 1% on FDA Approval for ACTEMRA Biosimilar | MT |
02-04 | Celltrion Secures FDA Approval for AVTOZMA Tocilizumab Biosimilar | MT |

Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- A068270 Stock
- News Celltrion, Inc.
- Celltrion, Inc. authorizes a Buyback Plan.